Nuvo Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nuvo Pharmaceuticals, Inc.
Dr Reddy’s has announced the launch of the first US generic version of Vimovo delayed-release tablets. However, Nuvo has warned that the at-risk launch infringes patents protecting the arthritis pain treatment until May 2022.
Three generics players in the US have helped to clear the path for generic rivals to the Vimovo analgesic by winning an appeals verdict of written descriptions for two patents.
Antibody developer Harbour Biomed signs its first deal for rights outside China in cancer pact with Kelun. Portage buys SalvaRx to increase its immuno-oncology capabilities, while Paragon spinout Emalex will take over Psyadon’s pediatric Tourette syndrome program.
Emergent gets vaccines for cholera and typhoid fever in PaxVax buyout. By taking over the OvaScience shell to go public, Millendo expects to take lead candidate livelotide into a pivotal study early next year.
- Medical Devices
- Drug Delivery
- OTC, Consumer
- Specialty Pharmaceuticals
- Controlled Release
- Topical Delivery
- Other Names / Subsidiaries
- Dimethaid Research
- Nuvo Research, Inc.
- Oxo Chemie GmbH
- Tribute Pharmaceuticals Canada Inc.
- ZARS Pharma, Inc., Nuvo Ireland